I agree with you Dr. Glaucomflecken , our program directors need to have balance instead of unipolar approach on research. I enjoy working with the students who are easy going compared to tons of research but no clarity or intention on clinical & humanity. Best way I assess

Love this .... some wisdom of retired #radonc docs in press in IJROBP - The Red Journal 💕 ASTRO Sue Yom redjournal.org/article/S0360-…

Pearls for talking to patients: 1) AI for 5 years is the goal, more has modest benefits. 2) 5 additional years reduces recurrence risk by 3-4%, most of these are new breast events 3) reduces distant recurrence by 2% (5 more years) 4) no OS benefit

New fastest shortest-path algorithm in 41 years! Tsinghua researchers broke Dijkstra’s 1984 “sorting barrier,” achieving O(m log^(2/3) n) time. This means faster route planning, less traffic, cheaper deliveries, and more efficient networks - and a CS curriculum revamp =)

Fascinating phase III trial of nasal mupirocin to reduce oral mucositis (OM) in patients receiving radiotherapy (almost all CRT) for NPC. Staph aureus growth on treatment has been implicated in oral mucositis, and we know that probiotics seem to be effective.

Excited to share our Hadassah new publication in Radiotherapy & Oncology 📄: another step toward globalizing proton therapy and making it accessible worldwide. So many people behind this work, but most important are the patients we serve. thegreenjournal.com/article/S0167-…

Phil Blumenfeld Hadassah That’s great! Make sure to spare the skin on your new machine. Don’t do what northwestern did with their breast patients giving them 100% IDL to the skin and being surprised by toxicity.

Are people still commonly doing 2D / 2 field 3D for early glottic? I have been doing VMAT/IMRT for 7 years now. Skin toxicity is way better with IMRT. #radonc

The 4-Field was a CC Wang/MGH technique to improve conformality in the 2D-3D era. It's my go-to if treating the whole larynx but IMRT is denied. Clearly better than laterals but still worse than IMRT. I can't wait for when we can talk about involved/single-cord treatment versus

⚡️New glioblastoma study: NRG BN007 (Phase II, n=159) - newly diagnosed MGMT-unmethylated glioblastoma, KPS ≥70, RT+Ipi+Nivo vs RT+TMZ ▶️PFS: 7.7 mo (Ipi+Nivo) vs 8.5 mo (TMZ) ❌ (HR 1.47, p=.96) ▶️OS ~13 mo in both arms ❌ 🛑 Accrual closed, no Ph III planned 📊 This adds

New in #practicalRO: A Case of Hydrogel Spacer Intravasation of the Internal Iliac Vein and Associated Thrombus Formation During Preparation for Prostate Cancer External Beam Radiation Therapy. #radonc tinyurl.com/proeckstein

Radiation Forgiveness & Re-irradiation & Monkeys 🙈🙊🙉 ============ I derived a simple equation to use "in clinico" TL;DR: To calculate spinal cord re-RT forgiveness,

Calling all #RadOnc #residents. In honor of Dr Brian Moran, a pioneer in #prostatecancer, ABS is offering a pathway in LDR prostate #brachytherapy. 10/15-18 Palm Desert. $1,000 travel stipend, free registration & expert-led training. bit.ly/3JcNoVE #RadOncResidents

Attention #RadOnc applicants for #MATCH2026, join our #radonc residents for a virtual Meet & Greet on Tuesday August 26th, 2025 from 7-8pm EST. We look forward to meeting you and answering your questions! Sign up: tinyurl.com/UKRadOncOpenHo…

After using #AI for 3 months to help find polyps, physicians were 6% less likely to find polyps on their own without AI. Do you think AI leads to a loss of skills ?

Excellent editorial on the DADSPORT meta-analysis: sciencedirect.com/science/articl…

How tight can SBRT prostate margins go? ⏱ ≤8 min → 4–5 mm = safe ⚠️ 2–3 mm = real-time tracking mandatory Our analysis on 192 prostate SBRT fractions and 2 motion monitoring systems is finally out. aapm.onlinelibrary.wiley.com/doi/10.1002/mp… American Association of Physicists in Medicine EFOMP ASTRO ESTRO OncoDaily

❗️ CONKO-007 Ph 3 RCT: FOLFOX or Gem -> continued chemo vs CRT (50.4 Gy + Gem); surgery if possible Primary endpoint: R0 18% vs 25% in favor of CRT In patients who underwent surgery: 69.4% CRT compared with 50.0% chemotherapy alone ascopubs.org/doi/full/10.12…

Resubmitting to a journal you swore to avoid forever

Like LAP07, CONKO-007 showed no OS benefit w standard dose chemoRT in LAPC. 5-yr OS numerically better (10 vs 3%), but # v small. Results form basis of control arm for LAP100, w dose-escalated RT as experimental reg. 1 endpt also 3 yr (not median) OS given ? delayed RT benefit.